Alnylam Pharmaceuticals and Quark Pharmaceuticals emerged as leading players in this domain. It is worth mentioning that Alnylam Pharmaceuticals is a large company that has an experience of over 17 years in developing RNAi based drug candidates. The company has a robust pipeline with two marketed drugs, Onpattro and Givosiran. Further, Onpattro has been marketed across US, Europe, Canada and Japan, for the treatment of genetic disorders, while Givosiran is presently approved in the US alone. Alnylam’s pipeline consists of a total of 11 drug candidates, out of which four are currently in phase II/III and above; these are Fitusiran (phase III), Inclisiran (phase III), Lumasiran (phase III) and Vutrisiran (phase III). The company is currently developing drug candidates for eight therapeutic areas, including (in alphabetical order) cardiovascular disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, metabolic disorders, oncology and others. In addition, Alnylam has developed its proprietary delivery technology, ESC-GalNAc, which is being used to develop the company’s potential drug candidates. Majority of the RNAi therapeutics being evaluated in phase I (22%) and phase II (26%) trials target oncological indications.
To request sample pages, please visit : https://www.rootsanalysis.com/reports/278/request-sample.html
Quark Pharmaceuticals, established in 1994, is a mid-sized company. It is worth noting that, close to 30% of the company’s pipeline candidates are currently in various phases of clinical development; examples of its clinical stage molecules are QPI-1002 (phase III), QPI-1007 (phase III) and PF-655 (phase II). The company has licensed a technology from Dicerna Pharmaceuticals that enables them to deliver QPI-1002 and PF-655 in the form of naked siRNA. Quark has also developed its proprietary delivery technology, BiFAR target discovery platform, which it intends to use for other pipeline molecules. Currently, pipeline molecules of the company target six therapeutic areas, including (arranged in alphabetical order) cardiovascular disorders, dermatological disorders, oncology, ophthalmic diseases, respiratory disorders and others. In 2019, the projected market is worth USD 160 million. We expect the overall RNAi therapeutics market to be worth USD 3.9 billion by 2025 and this value is projected to reach USD 9.2 billion by 2030.
Other companies with high competitiveness are (in decreasing order) Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Olix Pharmaceuticals, Sirnaomics, Gradalis and Souzhou Ribo Life Sciences; interestingly, pipeline molecules of these companies target at least five therapeutic areas, except Gradalis. However, Gradalis still has high pipeline strength owing to its clinical pipeline and proprietary delivery technology, vigil. It is worth mentioning that, even though these companies are significantly less experienced, they have strong pipeline for RNAi based therapeutics, which target different therapeutic areas.
Drug developers heavily rely on a number of broadcasting channels, which include direct to consumer (DTC) advertisements, product websites and conferences, to promote their proprietary drugs. The importance of such promotions is evident from the fact that the pharmaceutical industry spent close to USD 6.1 billion in DTC advertisements in 2017 The target of such promotional content / campaigns is usually consumers (patients), caretakers / caregivers and healthcare professionals (physicians). However, it is important to highlight that DTC advertising of prescription drugs is permitted only in the US, New Zealand, Bangladesh and South Korea. In other geographies, such as Europe, such promotional campaigns are not allowed, owing to the belief that advertisements may put physicians in a situation where they are likely to be coerced into prescribing advertised drugs based on patients’ demands, even if they are not the better alternatives. Additionally, other concerns include increase in healthcare costs related to promotional activities, as healthcare is completely reimbursed by the government in some countries.
Rnai Therapeutics market size – The “RNAi Therapeutics Market (2nd Edition), 2019-2030: Focus On siRNA, miRNA, shRNA and DNA” report features an extensive study of the current market landscape and future opportunities associated with RNAi therapeutics.
Channels used for Promotional Campaigns
Currently, there are a number of channels available for use by drug developers to promote their products. Some of these channels are mentioned below:
- Product websites: In order to provide the necessary information related to drugs to patients and healthcare professionals, drug developers launch product specific websites. The primary objective of such portals is to provide details on different aspects, such as indications for which the product can be used, its efficacy, benefits and safety concerns.
- Patient assistance programs: Drug makers generally initiate patient assistance programs in order to help less privileged patient groups get access to their drugs. In such cases, drug developers may offer to pay half or full price of the product for a specified period of time. The objective of such patient assistance programs is to support patients financially, as well as to provide day to day living assistance during the course of the treatment.
- Detailing material (face to face sales and promotional activities): Detailing material, such as leaflets and brochures, containing information on the drug, is another promotional strategy used by pharmaceutical companies. The objective of this strategy is to educate physicians about a specific product, with the expectation that the physician will prescribe the drug to his / her patients, who are suffering from the indication for which the drug is approved.
- Direct to consumer (DTC) advertisements: Promotional campaigns of prescription products that directly target consumers (patients) are known as DTC advertisements. Drug developers generally advertise their products using popular media platforms, such as television, print media (magazines and newspapers) and even over the radio. The main objective is to make patients familiar with the product and provide information on indication(s) for which it can be used, along with efficacy and / or safety results.
Oral / poster presentations at conferences: Conferences, held at the national or international level, present opportunities to drug developers to present their clinical findings generated from different clinical programs of the drug. Companies participate in such conferences to increase awareness about their initiative and respective drug products, among healthcare professionals.
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
You may also be interested in the following titles:
- Brain Concussion Market, 2021-2031
- Hunter Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Pediatric Brain Tumors: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
- Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
